DPX-COVID-19 / BioVaxys - LARVOL DELTA

IMV Inc. Announces Fourth Quarter and Full Year 2020 Financial and Operational Results (World Health Organization) - "Research and development expenses were $26.6 million for the year ended December 31, 2020...This increase of $7.6 million was mainly due to a rise in expenses related to the ongoing basket trial, personnel costs due to an increase in headcount, and pre-clinical development of DPX-COVID-19...Government assistance totaled $6.7 million for fiscal 2020...This increase is mainly explained by various government grants for the development of DPX-COVID-19, reimbursed for eligible development expenditures incurred to date."

Commercial • Infectious Disease • Novel Coronavirus Disease

IMV Inc. Announces Third Quarter 2020 Financial Results and Provides Clinical Update (Businesswire) - "Upcoming Milestones: DPX-COVID-19: Initiation of Phase 1/2 clinical trial with DPX-COVID-19 in 2020; Preliminary Phase 1/2 results in Q1 2021....Research and development expenses increased by $889,000 during the quarter ended September 30, 2020, compared to Q3 2019. These increases are mainly due to pre-clinical development for DPX-COVID-19."

Commercial • P1/2 data • Infectious Disease • Novel Coronavirus Disease

IMV Provides Updates On COVID-19 Vaccine Program (Businesswire) - "National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) is providing advisory services and up to $5.4 million in funding....In consultation with Health Canada, IMV decided to combine its original Phase 1 and 2 studies into a single trial with the potential to accelerate the clinical development and the timeline of the overall project....The design of this larger study will incorporate the same two-age strata cohorts....The Phase 1/2 trial is expected to be initiated before the end of 2020....IMV has entered a collaboration with a global manufacturing partner and initiated transfer and scale-up activities of DPX-COVID-19."

Clinical protocol • Financing • Licensing / partnership • Infectious Disease • Novel Coronavirus Disease

IMV Updates Rapid Progress on COVID-19 Vaccine Program (IMV Press Release) - "IMV Inc....provides further details today on the Company’s rapid progress in developing its candidate vaccine....'We are working closely with regulatory agencies and our collaborators to initiate clinical studies as quickly as possible. The design of the phase 1 clinical study, agreed with Health Canada, is a randomized controlled study, assessing the safety and immunogenicity of DPX-COVID-19, in 84 healthy adults across two age cohorts....Next milestones are anticipated as we commence phase 1 clinical trials this summer with results in the Fall of 2020. Once results are published, we plan to initiate phase 2 clinical trials in the second half of the year."

New P1 trial • P1 data • Infectious Disease • Novel Coronavirus Disease

IMV announces selection of a vaccine candidate against Covid-19 to advance into human clinical studies (Businesswire) - "...IMV conducted a pre-Clinical Trial Application (CTA) meeting with Health Canada and is finalizing a design for a Phase 1 clinical study of DPX-COVID-19. The randomized, placebo-controlled study is expected to enroll approximately 84 healthy subjects in two age strata and to assess two different doses of DPX-COVID-19. The Company is on track to initiate this study in the summer of 2020."

Canadian regulatory • New P1 trial • Infectious Disease • Novel Coronavirus Disease

IMV Inc. provides updates on the development of DPX-COVID-19 vaccine and ongoing business and clinical operations (Businesswire) - "In collaboration with Gary Kobinger, Ph.D....preclinical assays in animal models are also planned in April through May of this year....In collaboration with Joanne Langley, M.D. at the Canadian Center for Vaccinology (CCfV) and the Canadian Immunization Research Network (CIRN) the design of a Phase 1 clinical study in 48 healthy subjects has been completed and clinical sites identified in both Nova Scotia and Quebec. IMV has initiated discussions with Health Canada in preparation for a Clinical Trial Application (CTA). A meeting is being scheduled in the week of April 20, 2020 with the goal to initiate the clinical study in the summer of 2020."

Canadian regulatory • New P1 trial • Preclinical

Imv Inc launches plans to advance clinical development of a vaccine candidate against Covid-19 (Reuters) - "IMV Inc...intends to develop its vaccine candidate DPX-COVID-19 in collaboration with lead investigators for the phase 1 clinical study."

New P1 trial

Newly added product (Pharmaceutical-technology.com) - Preclinical, Novel Coronavirus Disease

Pipeline update